

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS; AND (2) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (the “**Director(s)**”) of Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that each of Dr. GUO Zijian (郭子建) (“**Dr. Guo**”) and Mr. WEI Kevin Cheng (蔚成) (“**Mr. Wei**”) has tendered his resignation from the position as an independent non-executive Director with effect from June 30, 2025, due to their personal commitments and other work commitments.

Each of Dr. Guo and Mr. Wei has confirmed that he has no disagreement with the Board, nor was there any matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its gratitude to Dr. Guo and Mr. Wei for their valuable contributions to the Company during their tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Board hereby announces that Ms. WONG Yan Ki Angel (黃欣琪) (“**Ms. Wong**”) and Dr. GAO Xiang (高翔) (“**Dr. Gao**”) have been appointed as independent non-executive Directors with effect from June 30, 2025.

The biographical details of Ms. Wong and Dr. Gao are set forth below:

Ms. WONG Yan Ki Angel (黃欣琪), aged 53, has 30 years of experience in accounting, auditing, corporate finance and capital market. Ms. Wong joined Kwan Wong Tan & Fong in October 1995, which later merged with Deloitte Touche Tohmatsu in August 1997, and resigned from Deloitte Touche Tohmatsu in November 1999. She later served a number of roles at Great East Packaging Holdings Limited (偉東包裝製品集團有限公司) from October 1999 to March 2003, including group financial controller and assistant finance manager. Between April 2003 and December 2007, she held various positions at Benefit Capital Limited (百富達融資有限公司) including vice president and executive director. From April 2005 to November 2005, she also acted as chief financial officer of Shengda (Group) Holdings Ltd (勝達國際控股有限公司). Since November 2007, Ms. Wong has been an executive director of Advanced Capital Limited (匯財資本有限公司), where she is responsible for operation management and major decisions.

Currently, Ms. Wong is an independent non-executive director in (i) Betta Pharmaceuticals Co., Ltd. (貝達藥業股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300558), since January 2021; (ii) Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd. (國鴻氫能科技(嘉興)股份有限公司), a company listed on the Stock Exchange (stock code: 9663), since October 2022; and (iii) Henan Jinyuan Hydrogenated Chemicals Co., Ltd. (河南金源氫化工股份有限公司), a company listed on the Stock Exchange (stock code: 2502), since October 2023, respectively.

Previously, Ms. Wong also held directorships in various public companies listed in different regions. From August 2009 to January 2011, she served as a non-executive director of Esmart Holdings Limited (currently known as Duty Free International Limited), a company listed on The Stock Exchange of Singapore Dealing and Automated Quotation System (stock code: DutyFree), during which she acted as the chairlady of the board from February 2010 to January 2011. Ms. Wong served as an independent non-executive director of the below companies:

- (i) China Best Group Holding Limited (國華集團控股有限公司) (currently known as Hong Kong Robotics Group Holding Limited (港仔機器人集團控股有限公司), a company listed on the Stock Exchange (stock code: 0370), from June 2011 to September 2014;
- (ii) Oriental Unicorn Agricultural Group Limited (東麟農業集團有限公司) (currently known as China Demeter Financial Investments Limited (國農金融投資有限公司)), a company listed on the GEM of the Stock Exchange (stock code: 8120), from October 2011 to May 2013;
- (iii) Hengxing Gold Holding Company Limited (恆興黃金控股有限公司), a company listed on the Stock Exchange (stock code: 2303, which was privatized and delisted in February 2021), from March 2013 to February 2021;
- (iv) China Shengda Packaging Group Inc. (中國勝達包裝集團有限公司), a company listed on the Nasdaq Stock Exchange (stock code: CPGI, which was privatized and delisted in September 2015), from August 2014 to September 2015;
- (v) BIT Mining Limited (formerly known as 500.com Limited), a company listed on the New York Stock Exchange (stock code: BTCM), from November 2015 to April 2023;
- (vi) China Public Procurement Limited (中國公共採購有限公司) (currently known as Cherish Sunshine International Limited (承輝國際有限公司)), a company listed on the Stock Exchange (stock code: 1094), from December 2015 to July 2018;
- (vii) Yuhua Energy Holdings Limited (裕華能源控股有限公司) (currently known as Jintai Energy Holdings Limited (金泰能源控股有限公司)), a company listed on the Stock Exchange (stock code: 2728), from November 2016 to December 2018;
- (viii) Miko International Holdings Limited (米格國際控股有限公司), a company listed on the Stock Exchange (stock code: 1247), from July 2017 to July 2018; and
- (ix) Many Idea Cloud Holdings Limited (多想雲控股有限公司), a company listed on the Stock Exchange (stock code: 6696), from October 2022 to June 2025, respectively.

Ms. Wong obtained a bachelor of economics in international accounting, from Xiamen University (廈門大學) in July 1994, a post-graduate certificate in professional accounting from the City University of Hong Kong in November 2000 and an executive master degree of business administration from Cheung Kong Graduate School of Business (長江商學院) in October 2009. Ms. Wong obtained the certificates of follow-up training courses for independent directors of listed companies from the Shenzhen Stock Exchange in May 2022 and August 2024, and also obtained the pre-appointment training certificate for STAR Market independent directors from the Shanghai Stock Exchange in April 2023. Ms. Wong has been admitted as a member or fellow member of several associations. Ms. Wong has been successively admitted as fellow member of the Institute of Financial Accountants in the United Kingdom since October 2003, fellow member of the Society of Registered Financial Planners in Hong Kong since November 2003, member of the Hong Kong Institute of Directors since November 2014, fellow member of the Institute of Public Accountants (FIPA) (澳洲公共會計師協會資深會員) since April 2015, founding member of the Hong Kong Independent Non-executive Director Association (香港獨立非執行董事協會) since January 2016, fellow member of CPA Australia (澳洲會計師公會) since May 2017, member of the Guangdong Association of Management Accountants since December 2017, member of the Association of Chinese Internal Auditors in Hong Kong (香港華人內部審計師公會) since April 2022, and fellow member of the Institute of Certified Management Accountant (CMA) (澳大利亞註冊管理會計師協會) since June 2024, respectively.

Dr. GAO Xiang (高翔), aged 61, a veteran in China's biotech industry, with decades of experience bridging the realms of biotech entrepreneurship and corporate governance. Dr. Gao founded GemPharmatech Co., Ltd. (江蘇集萃藥康生物技術股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688046), in December 2017 and has been serving as its chairman since then.

Dr. Gao's early career was marked by his dedication to academic and laboratory research. From 1997 to 2000, he served as a research associate at the neuroscience center of University of North Carolina. Dr. Gao has been a professor at Nanjing University (南京大學) since March 2000, and was recognized a Yangtze River Scholar Distinguished Professor (長江學者獎勵計劃特聘教授) at the model animal research center in 2001, where he served as director from 2002 to 2012. Dr. Gao also served as the dean of the Nanjing Biomedical Research Institute of Nanjing University from 2009 to 2018, concurrently holding the position of director of the state key laboratory of pharmaceutical biotechnology. Beyond those roles, Dr. Gao was a director of the key laboratory of Model Animal and Disease Research (模式動物與疾病研究) of the Ministry of Education (MOE) from 2010 to 2015, and has been the director of the National Resource Center for Mutant Mice (國家遺傳工程小鼠資源庫) since 2002. Dr. Gao also holds multiple roles in academic societies, including, among others, member of the National Laboratory Animal Professional Committee (國家實驗動物專家委員會), and member of the steering committee of the International Mouse Phenotyping Consortium (國際小鼠表型分析聯盟). Dr. Gao has led numerous national research projects under, among others, the National 973 Program, 863 Program and Science and Technology Support Program. His outstanding contributions to scientific research have been recognized with prestigious awards, such as the National Science Fund for Distinguished Young Scholars (國家傑出青年科學基金), the Special Prize of the MOE Award for Scientific and Technological Progress (教育部科技進步特等獎) and the Second Prize of the State Scientific and Technological Progress Award (國家科技進步二等獎).

Dr. Gao obtained a bachelor's degree in zoology and a master's degree in biochemistry from Nanjing University in 1985 and 1988, respectively. He further obtained a Ph.D. in developmental biology and anatomy from Thomas Jefferson University in the United States in 1994. From 1994 to 1997, Dr. Gao successively conducted his postdoctoral research in Roche Institute of Molecular Biology and The Jackson Laboratory, both in the United States.

The Company entered into a letter of appointment with each of Ms. Wong and Dr. Gao, with an initial term of three years commencing from June 30, 2025, and continue thereafter until terminated by not less than three months' notice in writing served by either party on the other, which is subject to retirement by rotation and re-election at the annual general meeting of the Company pursuant to the articles of association of the Company, or vacation from office pursuant to any applicable laws from time to time. Each of Ms. Wong and Dr. Gao is entitled to receive a director's fee of RMB270,000 per annum which is subject to review by the Board with reference to their duties in the Company.

Save as disclosed above, as of the date of this announcement, each of Ms. Wong and Dr. Gao (i) does not hold any other position with the Company or its subsidiaries, nor have any relationship with any Directors, senior management, substantial shareholder or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company; (ii) has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any interest in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and (v) has not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

Both Ms. Wong and Dr. Gao have confirmed that they have met the independence guidelines set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, Ms. Wong and Dr. Gao have confirmed that there is no other matter relating to their appointments that needs to be brought to the attention of the Shareholders, and there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend its warmest welcome to Ms. Wong and Dr. Gao for their appointments to the Board.

CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

Following Dr. Guo and Mr. Wei's resignations as independent non-executive Directors, Dr. Guo has ceased to be a member of each of the audit committee of the Company (the "**Audit Committee**"), the nomination committee of the Company (the "**Nomination Committee**") and the strategy committee of the Company (the "**Strategy Committee**"), and Mr. Wei has ceased to be the chairman of the Audit Committee and a member of the remuneration committee of the Company (the "**Remuneration Committee**").

The Board hereby announces that Ms. Wong has been appointed as the chairwomen of the Audit Committee and a member of the Nomination Committee, and Dr. Gao has been appointed as a member of each of the Audit Committee, the Remuneration Committee and the Strategy Committee, with effect from June 30, 2025.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, June 30, 2025

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Ms. WONG Yan Ki Angel, Dr. GAO Xiang and Mr. WU Dong as independent non-executive Directors.